HIV Envelope Protein gp41
-
Subject Areas on Research
-
A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity.
-
A Single Substitution in gp41 Modulates the Neutralization Profile of SHIV during In Vivo Adaptation.
-
A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.
-
A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1.
-
A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion.
-
A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.
-
Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.
-
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
-
Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity.
-
An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120.
-
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
-
Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope.
-
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
-
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.
-
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody.
-
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.
-
Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection.
-
Characterization of a trimeric MPER containing HIV-1 gp41 antigen.
-
Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.
-
Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.
-
Comparison of anti-HIV-1 ADCC reactivities in infected humans and chimpanzees.
-
Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
-
Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein.
-
Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.
-
Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region.
-
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.
-
Design, expression, and immunogenicity of a soluble HIV trimeric envelope fragment adopting a prefusion gp41 configuration.
-
Development of an env gp41-based heteroduplex mobility assay for rapid human immunodeficiency virus type 1 subtyping.
-
Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8.
-
Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation.
-
Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
-
Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection.
-
Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection.
-
Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry.
-
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
-
Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes.
-
Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.
-
Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses.
-
Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion.
-
Evidence that mannosyl residues are involved in human immunodeficiency virus type 1 (HIV-1) pathogenesis.
-
Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41.
-
Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1).
-
Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region.
-
Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.
-
Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.
-
Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
-
Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.
-
Glycosylation site-specific analysis of clade C HIV-1 envelope proteins.
-
HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques.
-
HIV entry inhibitors: progress in development and application.
-
HIV fusion and its inhibition.
-
HIV vaccines. Magic of the occult?
-
HIV-1 Envelope Conformation, Allostery, and Dynamics.
-
HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism.
-
HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.
-
HIV-1 envelope glycoprotein trimers display open quaternary conformation when bound to the gp41 membrane-proximal external-region-directed broadly neutralizing antibody Z13e1.
-
HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria.
-
HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
-
HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence.
-
HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life.
-
HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.
-
Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.
-
Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies.
-
Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies.
-
Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes.
-
Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry.
-
Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state.
-
Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein.
-
In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.
-
Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses.
-
Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses.
-
Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
-
Induction of a nonproductive conformational change in gp120 by a small molecule HIV type 1 entry inhibitor.
-
Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41.
-
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.
-
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated.
-
Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages.
-
Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting.
-
Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates.
-
Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies.
-
Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.
-
Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials.
-
Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41.
-
Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41.
-
Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein.
-
Newer treatments for HIV in children.
-
Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens.
-
Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection.
-
Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.
-
Phenotypic Correlates of HIV-1 Macrophage Tropism.
-
Phylogenetic analysis of protease and transmembrane region of HIV type 1 group O.
-
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
-
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.
-
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.
-
Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41.
-
Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy.
-
Presence of diverse human immunodeficiency virus type 1 viral variants in Cameroon.
-
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.
-
Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution.
-
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex.
-
Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies.
-
Rational design of membrane proximal external region lipopeptides containing chemical modifications for HIV-1 vaccination.
-
Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein.
-
Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women.
-
Role of HIV membrane in neutralization by two broadly neutralizing antibodies.
-
Role of conserved gp41 cysteine residues in the processing of human immunodeficiency virus envelope precursor and viral infectivity.
-
Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564.
-
Screening the interactions between HIV-1 neutralizing antibodies and model lipid surfaces.
-
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.
-
Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions.
-
Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01.
-
Structural and functional features of the HIV envelope glycoprotein and considerations for vaccine development.
-
Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody.
-
Structural rearrangements in the transmembrane glycoprotein after receptor binding.
-
Structure and immune recognition of trimeric pre-fusion HIV-1 Env.
-
Structure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimer.
-
The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat.
-
The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
-
Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes.
-
Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.
-
Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.
-
Keywords of People